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Hypoxia-inducible factors (HIFs) are differentially regulated in tumor cells. While the current paradigm
supports post-translational regulation of the HIF-a subunits, we recently showed that hypoxic HIF-2a is
also transcriptionally regulated via insulin-like growth factor (IGF)-II in the childhood tumor neuro-
blastoma. Here, we demonstrate that transcriptional regulation of HIF-2a seems to be restricted to neural
cell-derived tumors, while HIF-1a is canonically regulated at the post-translational level uniformly across
different tumor forms. Enhanced expression of HIF2A mRNA at hypoxia is due to de novo transcription
rather than increased mRNA stability, and chemical stabilization of the HIF-a proteins at oxygen-rich
conditions unexpectedly leads to increased HIF2A transcription. The enhanced HIF2A levels do not
seem to be dependent on active HIF-1. Using a transcriptome array approach, we identiﬁed members of
the Peroxisome proliferator-activated receptor gamma coactivator (PGC)/Estrogen-related receptor (ERR)
complex families as potential regulators of HIF2A. Knockdown or inhibition of one of the members, ERRa,
leads to decreased expression of HIF2A, and high expression of the ERRa gene ESRRA correlates with poor
overall and progression-free survival in a clinical neuroblastoma material consisting of 88 tumors. Thus,
targeting of ERRa and pathways regulating transcriptional HIF-2a are promising therapeutic avenues in
neuroblastoma.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Solid tumors frequently develop regions of hypoxia e low oxy-
gen tensions e as highly proliferating tumor cells tend to outgrow
the formation of new blood vessels within the tumor. Transformed
and normal cells mainly adapt to hypoxic surroundings via stabi-
lization of the oxygen sensitive a-subunits of the hypoxia inducible
transcription factors (HIFs). Expression of HIF-1a and HIF-2a, as
well as overall tumor hypoxia, correlates with metastasis, drug
resistance and poor outcome in a number of different tumor forms,
including neuroblastoma [1e7]. Although HIF-1a and HIF-2a have
high sequence homology and share a large proportion of target
genes, accumulating evidence shows that the regulation, andan).
Inc. This is an open access article uaction, of these two proteins signiﬁcantly differ in tumor cells
[2,3,5,6,8e10].
The childhood tumor neuroblastoma is believed to originate
from dividing precursor cells of the sympathoadrenal cell lineage
during formation of the sympathetic nervous system (SNS). We
have previously shown that HIF-1a and HIF-2a proteins are
differentially expressed in neuroblastoma cells, with acute and
transient stabilization of HIF-1a, and prolonged expression of HIF-
2a during hypoxic conditions [2]. Presence of tumor cells with
intense HIF-2a staining correlates with aggressive and metastatic
disease, whereas HIF-1a expression rather correlates to favorable
disease in neuroblastoma [2,6]. In addition, HIF-2a is expressed in
peri-vascular niches in both neuroblastoma and glioblastoma
[5,11], whereas HIF-1a expression mainly is restricted to hypoxic
regions [11]. We have recently shown that HIF-2a is regulated at the
transcriptional level by insulin-like growth factor (IGF)-II in neu-
roblastoma, and that these two proteins are co-expressed in em-
bryonic neuroblasts of the developing human SNS [10].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A. Hamidian et al. / Biochemical and Biophysical Research Communications 461 (2015) 560e567 561Here, we show that hypoxia-induced expression of HIF2AmRNA
mimics protein expression patterns in a time-dependent manner
with increased levels over time and a rate shift around 48 h after
the hypoxic onset. While HIF1A mRNA levels decrease under pro-
longed hypoxia (at 1% O2) uniformly in a number of cultured tumor
cells (neuroblastoma, breast cancer, prostate cancer, renal cell car-
cinoma (RCC), and non-small cell lung carcinoma (NSCLC)),
increasedHIF2A expression is only observed in neuroblastoma cells.
The observed changes in HIF mRNA at hypoxia are not due to al-
terations in overall mRNA stability. In addition, chemical stabili-
zation of the HIF proteins at normoxia (21% O2) leads to increased
HIF2A, and decreased HIF1A mRNA levels, in conformity with re-
sults observed when cells are cultured at hypoxia. Using a quanti-
tative real time (qRT)-PCR based array, we identiﬁed members of
the Peroxisome proliferator-activated receptor gamma coactivator
(PGC)/Estrogen-related receptor (ERR) complex families as poten-
tial regulators of HIF2A. Knockdown or inhibition of speciﬁcally one
member, ERRa, downregulates HIF2AmRNA levels in normoxic and
hypoxic neuroblastoma cells. Supporting a role for ERRa in tumors
with an HIF-2a-driven aggressive phenotype, high expression of
the gene encoding ERRa, ESRRA, correlates with poor overall and
progression-free survival in a clinical neuroblastoma data set con-
sisting of 88 tumors.
2. Material and methods
2.1. Cells and reagents
Human neuroblastoma cell lines SK-N-BE(2)c and KCN-69n
(kind gifts from Drs. June Biedler, Memorial Sloan Kettering Can-
cer Institute and Robert Ross, Fordham University), breast cancer
cell line MCF7 (ATCC), prostate cancer cell line DU 145 (ATCC), renal
cancer cell adenocarcinoma cell line 786-0 (ATCC), and non-small
cell lung cancer cell line A549 (ATCC) were routinely grown as
monolayers in Minimal Essential (SKeN-BE(2)c, KCN-69n, MCF7),
RPMI-1640 (DU 145), F-12 Kaighn's modiﬁcation (A549), or Dul-
becco's Modiﬁed Eagle's (786-0) medium supplemented with fetal
bovine serum and antibiotics. For culturing of MCF7 cells, growth
mediumwas supplemented with sodium pyruvate, essential amino
acids and insulin. Hypoxia was generated in an InvivO2 hypoxia
workstation (Ruskinn Technologies) or a Whitley H35 Hypo-
xystation (Don Whitley Scientiﬁc). Cells were treated with Acti-
nomycin D (5 mg/ml, SigmaeAldrich), 2,20-dipyridyl (DIP) (200 mM,
SigmaeAldrich), or XCT790 (1e5 mM, SigmaeAldrich).
2.2. Transfection
Transfections were carried out in serum- and penicillin-free
OPTI-MEM medium (Gibco) using Lipofectamine 2000 (Invi-
trogen) as transfection reagent. For HIF knockdown studies, cells
were transfected with siRNA duplexes (50 nM, Ambion) targeting
HIF-1a or HIF-2a respectively, and as a control, the inverted or
scrambled HIF-1a sequence was used. Sequences as previously
described [12]. For ESRRA knockdown studies, siRNA against ESRRA
(s4830; Ambion) or a non-targeting control siRNA (siC #2, Ambion)
was used at ﬁnal concentrations of 5 nM.
2.3. Western blotting
Cells were lysed in RIPA supplemented with Complete Protease
Inhibitor (Roche Diagnostics). Proteins were separated by SDS/
PAGE and transferred to Hybond-C-Extra Nitrocellulosemembranes (Amersham). Antibodies are listed in Supplementary
Table S1.
2.4. Quantitative real-time PCR
Total RNA was extracted manually using the QIAshredder and
RNeasy Mini Kits (Qiagen) according to the manufacturer's
recommendation or automatically using Arrow (DiaSorin) with
Arrow RNA (Tissue Kit -DNA Free) Kit (DiaSorin). cDNA synthesis
and quantitative PCR analysis was performed as described [10].
Expression levels of reference genes (YWHAZ, SDHA and UBC for SK-
N-BE(2)c, KCN-69n, 786-0 and MCF7 cells; GAPDH for DU 145 cells;
and UBC, TBP and HPRT1 for A549 cells) were used to normalize
gene-of-interest expression [13]. Primer sequences are listed in
Supplementary Table S2.
2.5. Expressed transcription factor knockdown transcriptome PCR
array
The expressed transcription factor knockdown transcriptome
PCR array (Sabiosciences) was used to simultaneously investigate a
total of 270 known transcription factors. SYBR Green quantitative-
PCR analysis was performed in a 7300 Real-Time PCR system
(Applied Biosystems), to quantify expression of HIF2A and HIF1A
using GAPDH as a reference gene. Fold changes in expression as a
result of each siRNA treatment relative to negative siRNA control
were calculated and normalized to GAPDH in accordance to man-
ufacturer's instructions.
2.6. Statistical analyses
All values are reported as mean ± SEM from at least three in-
dependent experiments, unless otherwise stated. Two-sided stu-
dent's unpaired t test was used for statistical analyses and three
levels of signiﬁcance were used, *p < 0.05, **p < 0.01, ***p < 0.001.
No asterisk (*) or n.s. indicates no signiﬁcance. A publically available
data set containing 88 neuroblastomas [14] was acquired from R2:
microarray analysis and visualization platform (http://r2.amc.nl).
KaplaneMeier and logrank survival analyses were performed using
R statistical language and the survival package [15]. Bonferroni
correction for multiple testing was employed to account for sur-
vival group optimization.
3. Results
3.1. Hypoxia-induced transcriptional regulation of HIF2A is
restricted to neural-derived tumors
HIF proteins are differentially regulated in neuroblastoma with
HIF-1a present mainly at acute phases of hypoxia (4e24 h) after
which protein levels rapidly decline. HIF-2a, on the other hand, is
predominantly expressed at prolonged phases of hypoxia
(48e72 h) [2]. Here, we show that mRNA expression patterns of
HIF2Amimic HIF-2a protein expression in neuroblastoma cells with
continuous increase over time (Fig. 1A and [2]). HIF1AmRNA levels
on the contrary decrease over time, despite stabilization of the
protein at acute hypoxia (Fig. 1B). To verify transcriptional activity
of HIF-2a even after prolonged exposure to hypoxia, we analyzed
the expression of well-established [2] and strongly HIF-2-driven
target genes in neuroblastoma. Indeed, VEGFA and DEC1 mRNA
expression closely follows HIF2A expression, with highest expres-
sion at later time points (Fig. 1CeD).
Fig. 1. HIF2A, but not HIF1A, mRNA is elevated in neuroblastoma cells at hypoxia (AeB) HIF2A (A) and HIF1A (B) mRNAwas measured in neuroblastoma SK-N-BE(2)c cells cultured at
hypoxia (1% O2). (CeD) VEGFA (C) and DEC1 (D) mRNA expression was measured as down stream targets of HIF-2. (EeF) HIF2A (E) and HIF1A (F) mRNA expression in MCF7 breast
cancer, DU 145 prostate cancer, A549 non-small cell lung cancer and 786-0 renal clear cell carcinoma cells cultured at 21 or 1% O2 for 48 (MCF7, DU 145, 786-0) or 72 (A549) hours.
Relative mRNA expression was measured by qRT-PCR and data are presented as mean ± SEM from two (A549) or three independent experiments. Statistical signiﬁcance was
calculated using student's t test, *p < 0.05, **p < 0.01. No asterisk (*) indicates no signiﬁcance.
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expression in hypoxic neuroblastoma cells was a general tumor cell
phenomenon. In glioblastoma, another neural cell-derived tumor
with an apparent dependency on HIF-2a [5,16,17], it has been
suggested that HIF2A transcription is induced at hypoxia, in
particular in glioblastoma stem cell-enriched primary cultures
[5,18]. On the other hand, long-term hypoxic culturing of breast
cancer, prostate cancer, renal cell carcinoma, and non-small cell
lung carcinoma cell lines did not result in any signiﬁcant effects on
HIF2A mRNA (Fig. 1E). Transcription of HIF1A, however, is un-
changed or even decreased uniformly in all tumor forms investi-
gated (Fig. 1B,F and [5]).3.2. Differential changes in HIF mRNA levels are not due to mRNA
stability
To address if the increase in HIF2A mRNA levels at hypoxia was
due to altered mRNA stability or de novo transcription, we treated
neuroblastoma cells with actinomycin D, an inhibitor of RNA syn-
thesis [19,20] for 2, 4, and 6 h after an initial priming of cells for 72 h
at normoxia or hypoxia. There was no marked difference in either
HIF2A or HIF1AmRNA levels between cells cultured at normoxia or
hypoxia when RNA synthesis was blocked (Fig. 2). Thus, the overall
actinomycin D-induced decrease in both HIF2A and HIF1A mRNA
rather supports active transcription of the HIF genes. If the
Fig. 2. Altered HIF mRNA expression at prolonged hypoxia is not due to changes in mRNA stability. SK-N-BE(2)c cells were cultured at 21% or 1% O2 for 72 h. Post-72 h, cells were
harvested at the indicated time points following actinomycin D treatment. Relative mRNA expression was measured by qRT-PCR and data are presented as mean ± SEM from three
independent experiments; n.s. e not signiﬁcant.
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explained by increased mRNA stability, the difference in mRNA
levels between actinomycin D treated normoxic and hypoxic cells
would be substantial.
3.3. HIF protein stabilization leads to induced HIF2A mRNA
expression
Cells exposed to hypoxia initiate a switch in their transcriptional
program, mainly mediated via HIF-1 and HIF-2. In order to deter-
mine the effects on HIF mRNA expression solely by stabilization of
the HIFs and not by activating the complete hypoxic machinery, we
treated two neuroblastoma cell lines with 2,20-dipyridyl (DIP), an
iron chelator, at normoxia. This leads to inhibition of the iron-
dependent hydroxylation and subsequent degradation of the HIF
alpha subunits and instead, HIF-1a and HIF-2a are stabilized
(Fig. 3AeB and reviewed in Ref. [21]). Surprisingly, also HIF2A
mRNA expression is induced by DIP treatment (Fig. 3C), whereas
HIF1A mRNA levels decrease (Fig. 3D), mimicking the hypoxic
response (cf. Fig. 1AeB).
Considering that HIF2A and HIF1A mRNA levels consistently
display opposing expression patterns at hypoxia (Figs. 1AeB and 3
CeD), we knocked down these two transcription factors individu-
ally and looked at their mRNA expression. Indeed, knockdown of
HIF1A lead to increased transcription ofHIF2A, whereas knockdown
of HIF2A increased the transcription of HIF1A (Fig. 3E).
3.4. Transcription of HIF2A is regulated by ERRa
To further investigate the possible interregulation between
HIF2A and HIF1A, we used a commercially available quantitative
real time (qRT)-PCR based array, where 270 different transcription
factors (including HIF-1a and HIF-2a) have been knocked down
using RNAi techniques (Expressed transcription factor knockdown
transcriptome PCR array, Sabiosciences). When analyzing the ef-
fects on HIF mRNA after transcription factor knockdown, we could
conclude that HIF2A transcription seemed to be more complex than
that of HIF1A (ten vs. two hits, fold change cut-off at ± 4) (Table 1).
However, neither HIF1A nor HIF2A were identiﬁed as hits for po-
tential regulation of each other (Table 1).
Instead, we looked at the list of potential regulators of HIF2A
transcription and identiﬁed coactivator PGC-1b. Coactivators
constitute a complex array of factors on which transcriptional
regulation by gene- and cell-speciﬁc DNA-binding transcription
factors depend upon. Coactivators of the PGC-1 family, PGC-1a and
PGC-1b in particular, respond to multiple signals and enhance the
transcriptional activity of key transcription factors involved in
mitochondrial biogenesis, fatty acid utilization, electron transport
chain assembly and angiogenesis [22]. Coactivation of ERRa byPGC-1a/b has been shown to play a role in the angiogenic and
proliferative processes in tumors. More speciﬁcally, all members of
the ERR family have been reported to physically interact with the
HIFs in breast cancer, and the speciﬁc interaction between ERRa/
PGC-1a is known to drive HIF2A transcription in skeletal muscle
[22e24]. Since HIF-2a and HIF-1a are well-established inducers of
VEGF-A and other pro-angiogenic factors, the PGC and ERR family
members as potential regulators of HIF2A transcription were of
particular interest. We could not establish a link between HIF2A
transcription and PGC-1a, PGC-1b or ERRg based on knockdown
studies in neuroblastoma cells. However, RNAi-mediated knock-
down of ERRa resulted in downregulated HIF2A mRNA levels both
at normoxia (Fig. 4A) and hypoxia (Fig. 4B). To further validate the
possible effects of ERRa on HIF2A transcription, we treated neuro-
blastoma cells with the ERRa inverse agonist XCT790. Expression of
HIF2A mRNA decreased in an inhibitor concentration-dependent
fashion (Fig. 4C). Of note, ESRRA mRNA levels were not affected
by hypoxia (Fig. 4C).
3.5. Expression of ESRRA correlates to disease stage and poor
prognosis in neuroblastoma
Having identiﬁed ERRa as a regulator of HIF2A transcription, we
sought to pinpoint if ERRa expression levels carried any prognostic
value in neuroblastoma. Using a publically available data set con-
sisting of 88 tumors [14], we could show that high expression of
ESRRA signiﬁcantly correlates to poor overall and progression-free
survival in neuroblastoma (bonf. p-values equal 0.014 and
0.00044, respectively) (Fig. 4DeE).
4. Discussion
We have recently established that HIF-2a is regulated at the
transcriptional level in neuroblastoma cells, likely in addition to the
canonical post-translational regulation that occurs in normal and
tumor cells [10]. Herewe establish that transcriptional regulation of
HIF2A is not a general tumor cell phenomenon, but rather appears
to be restricted to neurally derived tumors such as neuroblastoma
and glioblastoma. In addition, these tumors share the characteris-
tics of restricted areas with a pseudo-hypoxic phenotype with HIF-
2a positive tumor cells located in peri-vascular niches in tumor
specimens. High HIF-2a levels in neuroblastoma and glioblastoma
correlate with aggressive, disseminating disease and as knockdown
leads to impaired tumor growth in vivo in both these tumor forms
[2,5,11], HIF2A qualify as an oncogene. Interestingly, gain-of-
function mutations have been reported in two neuroblastoma-
related tumor forms, paraganglioma and pheochromocytoma
[25e30], further supporting an oncogenic role of HIF2A in neural
cell-derived tumors. These results highlight the importance of
Fig. 3. HIF1A and HIF2A show opposing mRNA expression patterns upon stabilization of HIF protein and knockdown of HIF mRNA. (AeB) SK-N-BE(2)c and KCN-69n cells were
treated with 202 dipyridyl (DIP) for 4 h at 21% O2 and protein expressionwas determined by western blot. Actinwas used as loading control. (CeD) Cells were treated as in (AeB) and
HIF2A (C) and HIF1A (D) mRNA was quantiﬁed. (E) Knockdown of HIF2A and HIF1A using siRNAs in SK-N-BE(2)c cells, followed by 72 h at 1% O2. As an internal control (siC) a
scrambled HIF-1a sequence was used. Quantiﬁcation of mRNA levels was performed using qRT-PCR. Data are presented as mean ± SEM from three independent experiments.
Statistical signiﬁcance was calculated using student's t test, **p < 0.01, ***p < 0.001. No asterisk (*) indicates no signiﬁcance.
Table 1
Genes altering the expression of HIF1A and HIF2A upon knock-down.
Gene symbol Description Possible effect Fold change
HIF1A Hypoxia inducible factor 1, alpha subunit Internal control for HIF1A 9,0
RUNX1 Runt-related transcription factor 1 Negative regulator candidate of HIF1A þ4,6
HDAC1 Histone deacetylase 1 Positive regulator candidate of HIF1A 5,3
EPAS1 Endothelial PAS domain protein 1 Internal Control for HIF2A 24,4
PRMT1 Protein arginine methyltransferase 1 Negative regulator candidate of HIF2A þ13,9
PRMT5 Protein arginine methyltransferase 5 Negative regulator candidate of HIF2A þ5,2
PPARGC1B Peroxisome proliferator-activated receptor gamma, coactivator 1 beta Negative regulator candidate of HIF2A þ5,2
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin Negative regulator candidate of HIF2A þ7,1
SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin Negative regulator candidate of HIF2A þ6,0
TCEAL1 Transcription elongation factor A Negative regulator candidate of HIF2A þ5,2
ZKSCAN1 Zink ﬁnger with KRAP and SCAN domains 1 Negative regulator candidate of HIF2A þ4,9
YY1 YY1 transcription factor Negative regulator candidate of HIF2A þ4,8
SMAD1 SMAD family member 1 Negative regulator candidate of HIF2A þ4,7
HDAC1 Histone deacetylase 1 Positive regulator candidate of HIF2A 5,1
Screening of HIF1A and HIF2A gene expression modulators using transcription factor knockdown transcriptome PCR arrays. Quantiﬁcation of HIF1A and HIF2A gene expression
levels using qRT-PCR are expressed as fold changes based on Ct calculations using GAPDH as a reference gene. Non-target siRNA treated sample wells served as negative
internal control. Data presented represent one experiment.
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2a in order to unravel novel therapeutic strategies for HIF-2a driven
aggressive tumor phenotypes.
There was no difference in the overall HIF mRNA stability be-
tween normoxic and hypoxic neuroblastoma cells, indicating that
the observed increase in HIF2A mRNA is explained by de novo
transcription. This result is supported by previous ﬁndings by Lin
et al., showing that HIF mRNA expression is insensitive to changesin mRNA stability [31]. In addition, these results support the notion
that induced expression of the HIF-2a protein at hypoxia to a large
part can be explained by enhanced HIF2A transcription and not
solely by protein stabilization.
Despite an acute stabilization of the HIF-1a protein, HIF1A
mRNA expression decreases in hypoxic neuroblastoma cells. Since
the effects on HIF1A mRNA is not explained by decreased mRNA
stability, it is tempting to speculate that the degradation of
Fig. 4. Transcription of HIF2A depends on ERRa activity. (AeB) Knockdown of ESRRA in SK-N-BE(2)c cells using siRNA, followed by 72 h of normoxia (21% O2, A) or hypoxia (1% O2, B).
(C) Treatment with ERRa inverse agonist XCT-790 for 72 h at hypoxia with indicated concentrations of XCT-790. Normoxic cells were used as an internal control for HIF2A
expression. Relative mRNA expression was measured by qRT-PCR and data are presented as mean ± SEM from three independent experiments. Statistical signiﬁcance was calculated
using student's t test, *p < 0.05, **p < 0.01, ***p < 0.001. No asterisk (*) or n.s. indicates no signiﬁcance. (DeE) High ESRRA mRNA expression in a clinical neuroblastoma material
consisting of 88 tumors correlate with poor overall (D) and progression free (E) survival. Bonferroni corrected logrank p-values are provided.
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decreased HIF1A mRNA expression patterns are repeated in a
number of different tumor forms that all stabilize the HIF-1a pro-
tein at hypoxia, conﬁrming an exclusive post-translational regula-
tory mechanism of HIF-1a in tumor cells.
Unexpectedly, stabilization of the HIF-a proteins at normoxic
conditions (by inhibiting the iron-dependent hydroxylation of the a
subunits), leads to increased HIF2A, and decreased HIF1A, mRNA
levels, mimicking the response observedwhen neuroblastoma cells
are cultured at hypoxia. This might suggest an autocrine-/paracrine
regulatory loop of the HIF transcription factors. Indeed, knockdown
of HIF-1a enhanced expression of HIF2A and vice versa, indicating
either direct or indirect interplay between these two proteins to at
least some extent. However, when analyzing the effect on HIF
mRNA levels after knockdown of 270 different transcription factors
(including HIF-1a and HIF-2a), neither HIF1A nor HIF2A were
identiﬁed as hits for possible regulation of each other. Considering
the somewhat modest effect seen after HIF knockdown using siR-
NAs (Fig. 3E), and the crude cut-off (>4-fold change in expression
levels) used for the transcriptome array, the effects that HIF-1a and
HIF-2a might have on each other would probably be too small for
detection by this methodological approach.
Of the potential regulators that were identiﬁed, PGC-1b was of
particular interest due to the known role of the PGC-1/ERR family
members in angiogenesis [32], and regulation of HIF expression in
skeletal muscle [24]. The consequent downregulation of HIF2A
mRNA expression after knockdown or inhibition of ERRa, and the
strong correlation between high expression of ESRRA and poor
overall and progression-free survival in neuroblastoma strongly
suggest that ERRa plays a role in aggressive neuroblastoma
behavior. Interestingly, ESRRAwas recently identiﬁed as one of the
most strongly expression-correlated regulators in an integrative
analysis of 111 reference human epigenomes [33]. When each
regulator was linked to the cell/tissue type that they most highly
correlated with, ESRRAwas found to have a regulatory relationship
exclusively with the fetal adrenal gland [33], the organ in which
more than half of all neuroblastomas arise. Hence, ERRa appears
highly relevant in neuroblastoma and serves as a potential thera-
peutic target for aggressive tumor growth in patients.
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